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Background:  Acute  pancreatitis  (AP)  is  the  most  common  complication  after  endoscopic  retrograde
cholangiopancreatography  (ERCP).  Statins  have been  traditionally  associated  to an  increased  risk  of  AP,
however, recent  evidence  suggests  that  statins  may  have  a protective  role  against  this  disease.
Aims:  Our  primary  aim  is to investigate  whether  the  use of  statins  has  a protective  effect  against  post-
ERCP  pancreatitis  (PEP).  Secondary  outcomes  are: to  evaluate  the  effect  of  other  drugs  on  the  incidence
of  PEP; to ascertain  the  relationship  between  the  use  of  statins  and  the  severity  of  PEP; and to  evaluate
the  effect  of  other  risk  and  protective  factors  on  the  incidence  of PEP.
Methods:  STARK  is  an  international  multicenter  prospective  cohort  study.  Centers  from  Spain,  Italy,  Croa-
tia, Finland  and  Sweden  joined  this  study.  The  total  sample  size  will  include  about  1016  patients,  whichydroxymethylglutaryl-CoA reductase
nhibitors
revention
rophylaxis
was  based  on  assuming  a 5%  incidence  of PEP  among  non-statin  (NSt)  users,  a  1–3 ratio  of  statin  (St)
and  NSt  consumers  respectively,  a 70%  decrease  in  PEP  among  St  consumers,  an  alpha-error  of  0.05  and
beta-error  of  0.20.  All patients  aged  ≥18  years  scheduled  for  ERCP  will  be offered  to enter  the  study.
Discussion:  STARK  study  will  ascertain  whether  statins,  a safe,  widely  used  and  inexpensive  drug,  can
modify  the  incidence  of  PEP.
©  2018  Editrice  Gastroenterologica  Italiana  S.r.l.  Published  by Elsevier  Ltd.  All  rights  reserved.. Rationale and aims
Endoscopic retrograde cholangiopancreatography (ERCP) is the
ain endoscopic therapeutic procedure used for pancreaticobiliary
isorders. Acute pancreatitis (AP) is the most common complica-
ion after ERCP, with an incidence ranging 3.5–9.7%, and a mortality
∗ Corresponding author at: Helsinki University Hospital, Abdominal Center and
niversity of Helsinki, Department of Surgery, Haartmaninkatu 4, 00029, PL 340,
US, Helsinki, Finland.
E-mail address: taija.korpela@hus.ﬁ (T. Korpela).
ttps://doi.org/10.1016/j.dld.2018.07.042
590-8658/© 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. Allrate of 0.7% [1,2]. Numerous prospective studies and meta-analyses
have identiﬁed several patient-related and procedure-related risk
factors for post-ERCP pancreatitis (PEP), such as female gender,
previous AP or PEP, normal serum bilirubin, high number of can-
nulation attempts and time needed for cannulation [1]. Several
pharmacological agents have been investigated for the preven-
tion of PEP [3,4]. Current European Society of Gastrointestinal
Endoscopy guidelines recommend routine rectal administration of
diclofenac or indomethacin immediately before or after ERCP in all
patients and, in addition to this, the placement of a prophylactic
 rights reserved.
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ancreatic stent should be strongly considered in case of high risk
or PEP [1].
3-Hydroxy-3-methyl-glutaryl-coenzyme A (HMG co-A) reduc-
ase inhibitors (statins) are effective and commonly used
orldwide as a treatment for dyslipidemia [5], and increasing evi-
ence shows that statins also have anti-inﬂammatory effects [5,6].
arlier reports suggested a potential association of statins to an
ncreased risk of AP, however, several recent studies have demon-
trated that the use of statins may  actually be a protective factor
gainst AP [7–11]. A meta-analysis of randomized controlled trials
uggested that the use of statins is associated with a lower risk of
ancreatitis [9]. A large population-based study by Wu  et al. [8]
howed that simvastatin use was independently associated with a
educed risk of AP. A Danish population-based case-control study
ith 2576 ﬁrst-time admitted cases of AP and 25,817 age- and
ender-matched controls showed no increased risk of AP among
tatin users and hypothesized a protective effect [10]. Gornik et al.
11] reported that statin treatment reduced morbidity and mor-
ality in patients with AP. Furthermore, a new meta-analysis of
bservational studies demonstrated that statin use is not associated
ith an increased risk of AP, however, more studies are needed to
xplore the effect of statins [12]. Promising results towards statin
eneﬁcial effect on AP have also been shown in preclinical stud-
es [13,14]. Therefore, the relationship between use of statins and
isk of pancreatitis should be re-examined considering a potential
eneﬁcial effect. The hypothesis of this study is that the anti-
nﬂammatory effect of statins might actually reduce the incidence
f PEP. Thus, our main objective is to investigate the association
etween the use of statins and the incidence of PEP.
. Study design
The STatins and post-ERCP Acute pancreatitis RisK (STARK)
tudy is an international multicenter prospective cohort study eval-
ating the effect of the use of statins on the risk of PEP. The study is
arried out in Spain, Italy, Croatia, Finland and Sweden. This project
s part of the Pancreas 2000 Educational Program. The study was
pproved by The Ethics Committee for Clinical Research of each
articipating center. The number of study approval is EMP-PARA-
017-01. The study follows the good clinical practice guidelines and
he recommendations of the 2013 Declaration of Helsinki.
Inclusion criteria are the following: age ≥18 years and being
cheduled for ERCP, in addition having signed the informed con-
ent form. Patients unwilling to participate, with ongoing AP, with
urgically-altered biliary anatomy (such as hepaticojejunostomy or
holedocho-duodenostomy), with failure to reach the papilla and
atients undergoing ERCP for only stent removal or exchange will
e excluded. Independent variables recorded for the study include
ex, age, weight, height, smoking habit, alcohol intake, diabetes
nd related medications, previous AP and features related to it,
istory of chronic pancreatitis (CP), use of statins (length of use,
ype, dose and time to last dose consumed), other medications
heparin, nonsteroidal anti-inﬂammatory drugs (NSAIDs), ﬁbrates]
aken by the patient, indication for ERCP and ERCP features such as
revious ERCP with sphincterotomy, dilatation of extrahepatic bile
uct, serum bilirubin, precut sphincterotomy, pancreatic sphinc-
erotomy, failure to clear bile duct stones, intraductal ultrasound,
perator experience, periprocedural hydration, biliary cannulation
ime and cannulation attempts, Wirsung cannulation or injection,
eripapillary balloon dilation and type of sedation (Table 1).PEP was deﬁned according to the revised Atlanta classiﬁcation
s two of the following three criteria: (i) abdominal pain (acute
nset of pain often radiating to the back); (ii) serum lipase or amy-
ase at least three times the upper limit of normal range; and (iii)Disease 50 (2018) 1362–1365 1363
characteristic ﬁndings of acute pancreatitis on imaging [1,15]. No
ﬁnancial support is required for this observational study.
2.1. Study endpoints
2.1.1. Primary outcome
The main outcome is the incidence and relative risk of PEP
among statin (St) and non-statin (NSt) users.
2.1.2. Secondary outcomes
Secondary outcomes are: the effect of other drugs on the inci-
dence of PEP; the relationship between the use of statins and the
severity of PEP; and the effect of risk factors (gender, previous pan-
creatitis, age, non-dilated extrahepatic bile duct, absence of CP,
normal serum bilirubin, cannulation attempts duration, pancreatic
guidewire passages and injection, precut sphincterotomy, pancre-
atic sphincterotomy, balloon dilation of biliary sphincter, failure to
clear bile duct stones and intraductal ultrasound) and protective
factors (rectal administration of diclofenac or indomethacin and
placement of a prophylactic pancreatic stent) in the incidence of
PEP.
2.2. Statistical methods
The total sample size will include about 1016 patients, which
was based on assuming a 5% incidence of PEP among NSt users, a
1–3 ratio of St and NSt consumers respectively, and a 70% decrease
of PEP rate among St consumers [1,8,16]. Alpha-error was set
0.05 and beta-error 0.20. The STROBE guidelines for observational
studies will be followed to report our ﬁndings [17]. Data will be pre-
sented as mean (standard deviation), median (interquartile range)
or number (%) as appropriate. All statistical tests will be 2-tailed,
and P values of less than 0.05 will be considered statistically sig-
niﬁcant. The manuscript will contain the baseline characteristics
of the patients and analysis of the primary and secondary out-
comes of the study. The association between St users and PEP will
be analyzed in univariate analysis by means of Chi-squared test
and in multivariate analysis by means of binary logistic regression.
Incidence, Odds ratio (OR) (95% conﬁdence interval) and adjusted
OR (aOR) will be used as measures of the frequency and strength
of association of PEP among St and NSt users. The aOR will be
calculated by means of binary logistic regression, using the follow-
ing variables in the model: gender, age, previous pancreatitis, use
of rectal diclofenac or indomethacin, previous ERCP with sphinc-
terotomy, duration of cannulation attempts, pancreatic guidewire
passages, pancreatic injection, precut sphincterotomy, pancreatic
sphincterotomy, pancreatic duct stent placement and balloon dila-
tion of biliary sphincter. The frequency and percentage of missing
values for each variable will be collected, analyzed and reported
(missing value analysis). All data will be anonymous once data
collection is completed, respecting the conﬁdentiality of the sub-
jects participating, in accordance with data protection laws. Data
monitoring was performed for the STARK study.
3. Discussion
AP can range from mild discomfort to fatal illness and little is
currently known on how to prevent recurrent attacks. Many differ-
ent drugs have been tested to prevent PEP. Statins are a safe, widely
used and inexpensive group of drugs that have been associated to
a decreased risk of AP in recent studies. If statins protect against
AP, they could also have a protective role in the prevention of PEP.
STARK study aims to ﬁnd out whether statins can change the inci-
dence of PEP. Positive results in this observational study will also
justify future clinical trials aiming to determine whether statins are
1364 T. Korpela et al. / Digestive and Liver Disease 50 (2018) 1362–1365
Table 1
Data collection sheet.
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